Frequency-modulated electromagnetic neural stimulation (FREMS) as a treatment for symptomatic diabetic neuropathy: Results from a double-blind, randomised, multicentre, long-term, placebo-controlled clinical trial

E. Bosi, G. Bax, L. Scionti, V. Spallone, S. Tesfaye, P. Valensi, D. Ziegler

Research output: Contribution to journalArticle

Abstract

Aims/hypothesis: The aim was to evaluate the efficacy and safety of transcutaneous frequency-modulated electromagnetic neural stimulation (frequency rhythmic electrical modulation system, FREMS) as a treatment for symptomatic peripheral neuropathy in patients with diabetes mellitus. Methods: This was a double-blind, randomised, multicentre, parallel-group study of three series, each of ten treatment sessions of FREMS or placebo administered within 3 weeks, 3 months apart, with an overall follow-up of about 51 weeks. The primary endpoint was the change in nerve conduction velocity (NCV) of deep peroneal, tibial and sural nerves. Secondary endpoints included the effects of treatment on pain, tactile, thermal and vibration sensations. Patients eligible to participate were aged 18-75 years with diabetes for ≥1 year, HbA1c

Original languageEnglish
Pages (from-to)467-475
Number of pages9
JournalDiabetologia
Volume56
Issue number3
DOIs
Publication statusPublished - Mar 2013

Keywords

  • Diabetic neuropathy
  • Electrical stimulation
  • Nerve conduction studies
  • Neuropathic pain
  • Neurostimulation therapy
  • Randomised clinical trial

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Frequency-modulated electromagnetic neural stimulation (FREMS) as a treatment for symptomatic diabetic neuropathy: Results from a double-blind, randomised, multicentre, long-term, placebo-controlled clinical trial'. Together they form a unique fingerprint.

  • Cite this